State Board of Administration of Florida Retirement System grew its position in Loxo Oncology, Inc. (NASDAQ:LOXO) by 16.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,760 shares of the biopharmaceutical company’s stock after purchasing an additional 1,400 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Loxo Oncology were worth $899,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in LOXO. Teachers Advisors LLC raised its holdings in shares of Loxo Oncology by 27.2% in the 1st quarter. Teachers Advisors LLC now owns 28,162 shares of the biopharmaceutical company’s stock valued at $1,185,000 after purchasing an additional 6,023 shares in the last quarter. TIAA CREF Investment Management LLC raised its holdings in shares of Loxo Oncology by 9.7% in the 1st quarter. TIAA CREF Investment Management LLC now owns 40,772 shares of the biopharmaceutical company’s stock valued at $1,716,000 after purchasing an additional 3,614 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Loxo Oncology by 8.4% in the 1st quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 284 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Loxo Oncology by 42.8% in the 1st quarter. Vanguard Group Inc. now owns 733,248 shares of the biopharmaceutical company’s stock valued at $30,856,000 after purchasing an additional 219,837 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Loxo Oncology by 48.0% in the 1st quarter. Geode Capital Management LLC now owns 136,276 shares of the biopharmaceutical company’s stock valued at $5,734,000 after purchasing an additional 44,193 shares in the last quarter. Institutional investors and hedge funds own 99.31% of the company’s stock.

LOXO has been the topic of a number of analyst reports. BTIG Research restated a “buy” rating and issued a $75.00 price objective on shares of Loxo Oncology in a report on Thursday, August 3rd. Stifel Nicolaus restated a “buy” rating and issued a $71.00 price objective on shares of Loxo Oncology in a report on Thursday, August 3rd. BidaskClub lowered shares of Loxo Oncology from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Zacks Investment Research upgraded shares of Loxo Oncology from a “hold” rating to a “buy” rating and set a $82.00 price objective on the stock in a report on Wednesday, August 9th. Finally, Ifs Securities restated an “outperform” rating on shares of Loxo Oncology in a report on Tuesday, August 8th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Loxo Oncology has a consensus rating of “Buy” and a consensus price target of $90.57.

In related news, Director Keith T. Flaherty sold 7,250 shares of Loxo Oncology stock in a transaction on Monday, August 21st. The shares were sold at an average price of $72.26, for a total transaction of $523,885.00. Following the sale, the director now directly owns 20,432 shares in the company, valued at approximately $1,476,416.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Avi Z. Naider sold 5,000 shares of Loxo Oncology stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $90.00, for a total transaction of $450,000.00. Following the sale, the director now owns 154,118 shares in the company, valued at $13,870,620. The disclosure for this sale can be found here. Insiders have sold a total of 76,814 shares of company stock worth $6,548,261 over the last quarter. 44.40% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This story was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/state-board-of-administration-of-florida-retirement-system-grows-holdings-in-loxo-oncology-inc-loxo/1713561.html.

Shares of Loxo Oncology, Inc. (NASDAQ:LOXO) opened at $75.07 on Friday. Loxo Oncology, Inc. has a one year low of $25.25 and a one year high of $95.92.

Loxo Oncology Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.